Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | XDH | P47989 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8868807 | 0.92 | RAB9A (0.85) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL2011167 | 0.88 | RAB9A (0.79) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL289112 | 0.88 | SMN1; SMN2 (0.93) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL8867051 | 0.88 | RAB9A (0.79) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL1327631 | 0.88 | SMN1; SMN2 (1.00) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL8339818 | 0.87 | RAB9A (0.77) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL14018508 | 0.87 | RAB9A (0.77) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL12970049 | 0.87 | RAB9A (0.77) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL3436647 | 0.87 | RAB9A (0.77) | RAB9AKDM4EGAASMN1; SMN2NPC1 | |
| SCHEMBL2069278 | 0.87 | RAB9A (1.00) | RAB9AKDM4EGAASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | UNIV GEORGIA (US) | 2026-04-09 | — | — | US | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | CTXT PTY. LTD. (AU) | 2018-06-26 | — | — | US | disclosed |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | CTXT PTY. LTD. (AU) | 2017-11-02 | — | — | US | disclosed |
| EP-3190109-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2440550-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2016-11-10 | — | — | US | disclosed |
| US-9434722-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | AMGEN INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005086661-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-20040138271-A1 | Benzene compound and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| EP-1375472-A1 | BENZENE COMPOUND AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005792-B2 | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors | PRMT5, PRMT1, PRMT3 | RAB9A 1746/4885KDM4E 113/4885GAA 4881/4885 |
| US-20170313713-A1 | AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS | PRMT5, PRMT1, PRMT3 | RAB9A 1838/4885KDM4E 118/4885GAA 4881/4885 |
| US-20160324828-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | RAB9A 1770/4885KDM4E 2535/4885GAA 338/4885 |
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | RAB9A 3232/4885KDM4E 2818/4885GAA 4863/4885 |
| US-20060004012-A1 | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | PNLIP, IAPP, GPR119 | RAB9A 3240/4885KDM4E 4456/4885GAA 124/4885 |
| US-20260097046-A1 | PLASMODIUM FALCIPARUM BLOOD STAGE INHIBITORS | SUB1, PFN1, HCCS | RAB9A 1834/4885KDM4E 3780/4885GAA 4511/4885 |
| US-20040138271-A1 | Benzene compound and salt thereof | INSR, SLC5A1, IRS1 | RAB9A 3436/4885KDM4E 2258/4885GAA 3347/4885 |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | RAB9A 2956/4885KDM4E 3094/4885GAA 2303/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | RAB9A 1779/4885KDM4E 2485/4885GAA 346/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | RAB9A 1770/4885KDM4E 2535/4885GAA 338/4885 |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | RAB9A 3699/4885KDM4E 3724/4885GAA 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.